SPARC targets $10 million cost savings, consolidates R&D ops in Vadodara site

SPARC

• SPARC cuts costs, reduces workforce, and consolidates labs to save $10M annually
• Focus shifts to oncology, immunology assets; Vodobatinib deprioritized
• SBO-154 and SCD-153 advance in trials; key results expected by 2026

Did our AI summary help?

Sun Pharma Advanced Research Company (SPARC) is cutting costs and optimizing R&D amid a portfolio pivot to high-value oncology and immunology assets, targeting $10 million in annual savings while managing $46 million in debt, according to company's recent investor call.

The company is consolidating its operations in Vadodara, with US headcount slashed by over 80 percent, labs reduced from four to two sites, and overall workforce dropping 40 percent to around 246 by FY27 from 409 in FY24, driving R&D spend down to $14.3 million in FY25 from $20.4 million previously.

SPARC, which focused on drug discovery and development, is backed by Dilip Shanghvi and his family and has synergies with parent Sun Pharmaceutical Industries, while also relying on revenue from out-licensed products. The long R&D cycles require significant investment and occasional borrowing or cost optimization.

This hybrid captive-outsourced model extends the cash runway through FY27-28 via promoter-backed debt and internal accruals against a $125 million debt limit, while deprioritizing Vodobatinib in a competitive Chronic Myeloid Leukemia (CML) landscape to free resources for modular platforms. CML is a slow-growing blood cancer of the bone marrow

​

SPARC's R&D optimization emphasizes business model flexibility, including NewCo Tiller Therapeutics for SCO-155 SMDC (potential 55% equity stake) and early licensing for seven assets, narrowing from a post-PROSEEK focus to 10 prioritized programs leveraging cost-effective Indian trial infrastructure.

Lead oncology candidate SBO-154, an anti-MUC1-SEA antibody drug conjugate (ADC) with Monomethyl Auristatin E (MMAE) payload, advances in Phase 1a dose escalation (cohorts 1-2 complete, cohort 3 enrolling across US/Australia/India sites), targeting high-expression tumors in NSCLC, ER-breast, ovarian, and pancreatic cancers, with maximum tolerated dose readout by Q42026.

Immunology standout SCD-153, a first-in-class topical itaconate prodrug co-developed with JHU (Johns Hopkins University) and IOCB (Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, completed Phase 1b alopecia areata cohort 1 (safe foam formulation), with cohort 2 enrolling for topline Q4 2026 and vitiligo Phase 1b/2a initiation by Q3 2026 as a non-JAK alternative or JAKi adjunct.

​

The streamlined portfolio spans differentiated modalities—ADCs (SPARC122-125), bispecifics/bifunctionals (SPARC127-128), STING ISACs (SPARC126), DDR inhibitors for synthetic lethality (SPARC124/131), and SMDCs—prioritizing oncology's targeted delivery wave and immunology's safer topicals/combos for AA, vitiligo, and atopic dermatitis. Near-term catalysts like PRV voucher appeal outcome (Q1 2026), PDP-716 new drug application (NDA) resubmission result (Q1 2026), Tiller license agreement, and Phase 1b readouts position SPARC for clinical proof-of-concept and value inflection, bolstered by preclinical validations in TNBC (Triple-Negative Breast Cancer), GBM (Glioblastoma) and beyond.

​